search
Back to results

Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection

Primary Purpose

Enhanced Recovery After Surgery

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
TU-100
Placebo
Sponsored by
Tsumura USA
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Enhanced Recovery After Surgery

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female ≥ 18 years of age
  2. Women of childbearing potential (WOCBP) or men whose sexual partners are WOCBP; must be able and willing to use at least 1 highly effective method of contraception during the study and for 30 days after the last dose of study drug
  3. American Society of Anesthesiologists Physical Status Score of 1 to 3
  4. Scheduled for an elective BR via open or laparoscopic approach
  5. Ability to understand the study procedures, have agreed to participate in the study program, and have voluntarily provided informed consent

Exclusion Criteria:

  1. Scheduled for a BR that is not listed in this protocol
  2. Requires any additional resections beyond the intestine (eg, hepatectomy, distal pancreatectomy, pancreaticoduodenectomy, gastric resection, uterine resection), or concomitant surgeries (with the exception of biopsies)
  3. Requires the formation of a stoma (ileostomy or colostomy)
  4. History of surgeries, illness, or behavior (eg, depression, psychosis) that in the opinion of the investigator might confound the study results or pose additional risk in administering the study procedures
  5. Have a functional colostomy or ileostomy
  6. Diagnosed with advanced or metastatic colon cancer (Stage IV by tumor, node, and metastasis classification)
  7. Positive coronavirus disease 2019 (COVID-19) test
  8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including human immunodeficiency virus (HIV)), diabetes, symptomatic congestive heart failure and ejection fraction < 35%, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with protocol requirements
  9. Chronic pain syndrome unrelated to the planned surgery requiring consistent management with analgesics and/or other non-pharmacologic modalities
  10. Myocardial infarction within 3 months
  11. Corrected QT interval > 500 msec
  12. Diabetic gastroparesis
  13. Compromised immune system, either from treatment with corticosteroids or other immunosuppressive agent within 2 weeks of surgery or from immunosuppressive disease (HIV)
  14. Pregnant (identified by a positive serum pregnancy test) or lactating, or are not postmenopausal (no menses for at least 1 year) and are of childbearing potential and not using an accepted method of birth control (surgical sterilization, intrauterine contraceptive device, oral contraceptive, diaphragm, or condom in combination with contraceptive cream, jelly, or foam or abstinence)
  15. Participated in another investigational drug/biologic or medical device study within 30 days of surgery or will be enrolled in another investigational drug or medical device study, or any study in which active subject participation is required outside routine hospital data collection during the course of the study
  16. Illicit drug use or alcohol abuse based on medical history, or currently engaged in illicit drug use or alcohol abuse
  17. Uses of supplemental ginger, ginseng, or Zanthoxylum fruit within 72 hours before randomization
  18. Has a history of allergic reactions to ginseng, ginger, Zanthoxylum fruit, or lactose
  19. Has clinical symptoms of lactose intolerance after ingesting milk or milk-containing products (abdominal pain, flatulence, diarrhea)
  20. Unwilling or unable to comply with procedures described in this protocol or is otherwise unacceptable for enrollment in the opinion of the investigator
  21. Has a history of previous surgeries, illness (interstitial pneumonia), or behavior (depression, psychosis) that, in the opinion of the investigator, might confound the study results or pose additional risk in administering the study procedures

Sites / Locations

  • Florence SiteRecruiting
  • Gilbert SiteRecruiting
  • Little Rock SiteRecruiting
  • Duarte SiteRecruiting
  • Los Angeles Site #1Recruiting
  • Los Angeles Site #2Recruiting
  • Palo Alto SiteRecruiting
  • Sacramento SiteRecruiting
  • Danbury SiteRecruiting
  • Clearwater SiteRecruiting
  • Miami Site
  • Orlando SiteRecruiting
  • Tampa SiteRecruiting
  • Weston SiteRecruiting
  • Chicago Site #2Recruiting
  • Chicago Site #1Recruiting
  • Urbana SiteRecruiting
  • Lexington SiteRecruiting
  • Louisville Site
  • Metairie SiteRecruiting
  • Baltimore Site
  • Boston Site #2
  • Boston Site #1Recruiting
  • Detroit SiteRecruiting
  • St. Louis SiteRecruiting
  • Newark Site
  • Mineola SiteRecruiting
  • New York SiteRecruiting
  • Stony Brook SiteRecruiting
  • Cleveland Site #2Recruiting
  • Cleveland Site #1Recruiting
  • Dayton Site
  • Philadelphia Site #2Recruiting
  • Philadelphia Site #1
  • Pittsburgh SiteRecruiting
  • Charleston SiteRecruiting
  • Memphis SiteRecruiting
  • Dallas Site
  • Fort Worth SiteRecruiting
  • Salt Lake City SiteRecruiting
  • Roanoke SiteRecruiting
  • Milwaukee SiteRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

TU-100 15 g/day

TU-100 7.5 g/day

Placebo

Arm Description

Subjects will receive a total daily dose of TU-100 5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).

Subjects will receive a total daily dose of TU-100 2.5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).

Subjects will receive placebo TID until hospital discharge or ≤ 10 days (whichever is earlier).

Outcomes

Primary Outcome Measures

Time to gastrointestinal recovery (GIR)
Time to achieve recovery of GI motility as measured by a composite endpoint representing upper AND lower GI recovery

Secondary Outcome Measures

Time to GIR responses
Time to first toleration of clear liquids, time to transition from clear liquids to next diet stage (full liquids or solids), time to toleration of solids, time to first bowel movement, and time to absence of distension and presence of bowel sounds and flatus
GIR outcome related to length of hospitalization
Total number of calendar days from surgery to ready for discharge based solely on GI recovery
POI-related morbidity
Primary POI that is not secondary to surgical complication, such as anastomotic leak, abscess formation, or sepsis that requires readmission within 7 days of discharge, or need for postoperative nasal gastric tube insertion to manage symptoms of POI (vomiting/retching, abdominal distension)
Safety of TU-100
Patient incidence of adverse events (AEs) observed following administration of TU-100.

Full Information

First Posted
January 29, 2021
Last Updated
September 14, 2023
Sponsor
Tsumura USA
search

1. Study Identification

Unique Protocol Identification Number
NCT04742907
Brief Title
Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection
Official Title
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery (ERAS) Protocol in Subjects Undergoing Bowel Resection
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 29, 2021 (Actual)
Primary Completion Date
February 2024 (Anticipated)
Study Completion Date
March 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tsumura USA

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This multicenter, randomized, double-blinded, placebo-controlled study will evaluate the effect of TU-100 on resolution of postoperative ileus (POI) in subjects undergoing open or laparoscopic bowel resection (BR).
Detailed Description
Subjects will be screened up to 28 days before their planned surgery and will be randomized 1:1:1 (TU-100 15 g/day: TU-100 7.5 g/day: placebo) on postoperative Day 1 before the first dose of study medication. After randomization, subjects will receive a total daily dose of TU-100 15g, TU-100 7.5 g, or matching placebo (3 times per day (TID)) until hospital discharge or ≤ 10 days (whichever is earlier). All subjects will be treated with study medication as adjunct to an enhanced recovery (ERAS) pathway for gastrointestinal (GI) recovery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Enhanced Recovery After Surgery

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomized, Double-Blind, Placebo-Controlled
Masking
ParticipantInvestigator
Masking Description
Investigators, study staff, sponsor designees, and subjects will be blinded to randomized study treatment for the duration of the study. The pharmacist or designee performing the preparation and administration will also be blinded.
Allocation
Randomized
Enrollment
402 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TU-100 15 g/day
Arm Type
Experimental
Arm Description
Subjects will receive a total daily dose of TU-100 5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).
Arm Title
TU-100 7.5 g/day
Arm Type
Experimental
Arm Description
Subjects will receive a total daily dose of TU-100 2.5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will receive placebo TID until hospital discharge or ≤ 10 days (whichever is earlier).
Intervention Type
Drug
Intervention Name(s)
TU-100
Other Intervention Name(s)
Daikenchuto
Intervention Description
Treatment with investigational product
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Treatment with placebo product
Primary Outcome Measure Information:
Title
Time to gastrointestinal recovery (GIR)
Description
Time to achieve recovery of GI motility as measured by a composite endpoint representing upper AND lower GI recovery
Time Frame
From the day after surgery until hospital discharge or ≤ 10 days (whichever is earlier)
Secondary Outcome Measure Information:
Title
Time to GIR responses
Description
Time to first toleration of clear liquids, time to transition from clear liquids to next diet stage (full liquids or solids), time to toleration of solids, time to first bowel movement, and time to absence of distension and presence of bowel sounds and flatus
Time Frame
From the day after surgery until hospital discharge or ≤ 10 days (whichever is earlier)
Title
GIR outcome related to length of hospitalization
Description
Total number of calendar days from surgery to ready for discharge based solely on GI recovery
Time Frame
From surgery to hospital discharge based on GI recovery (up to 2 weeks)
Title
POI-related morbidity
Description
Primary POI that is not secondary to surgical complication, such as anastomotic leak, abscess formation, or sepsis that requires readmission within 7 days of discharge, or need for postoperative nasal gastric tube insertion to manage symptoms of POI (vomiting/retching, abdominal distension)
Time Frame
From the day after surgery to discharge follow-up visit (30 days (+ 7 days) after hospital discharge)
Title
Safety of TU-100
Description
Patient incidence of adverse events (AEs) observed following administration of TU-100.
Time Frame
From baseline to discharge follow-up visit (30 days (+ 7 days) after hospital discharge)
Other Pre-specified Outcome Measures:
Title
Effects of TU-100 on early postoperative surgical outcomes related to mechanism of action
Description
Subject-reported (electronic diary) for number of episodes of vomiting and/or retching per day and bothersome nausea and abdominal bloating by day, postoperative antiemetic rescue, and postoperative complications
Time Frame
From the day after surgery to discharge follow-up visit (30 days (+ 7 days) after hospital discharge)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female ≥ 18 years of age Women of childbearing potential (WOCBP) or men whose sexual partners are WOCBP; must be able and willing to use at least 1 highly effective method of contraception during the study and for 30 days after the last dose of study drug American Society of Anesthesiologists Physical Status Score of 1 to 3 Scheduled for an elective BR via open or laparoscopic approach Ability to understand the study procedures, have agreed to participate in the study program, and have voluntarily provided informed consent Exclusion Criteria: Scheduled for a BR that is not listed in this protocol Requires any additional resections beyond the intestine (eg, hepatectomy, distal pancreatectomy, pancreaticoduodenectomy, gastric resection, uterine resection), or concomitant surgeries (with the exception of biopsies) Requires the formation of a stoma (ileostomy or colostomy) History of surgeries, illness, or behavior (eg, depression, psychosis) that in the opinion of the investigator might confound the study results or pose additional risk in administering the study procedures Have a functional colostomy or ileostomy Diagnosed with advanced or metastatic colon cancer (Stage IV by tumor, node, and metastasis classification) Positive coronavirus disease 2019 (COVID-19) test Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including human immunodeficiency virus (HIV)), diabetes, symptomatic congestive heart failure and ejection fraction < 35%, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with protocol requirements Chronic pain syndrome unrelated to the planned surgery requiring consistent management with analgesics and/or other non-pharmacologic modalities Myocardial infarction within 3 months Corrected QT interval > 500 msec Diabetic gastroparesis Compromised immune system, either from treatment with corticosteroids or other immunosuppressive agent within 2 weeks of surgery or from immunosuppressive disease (HIV) Pregnant (identified by a positive serum pregnancy test) or lactating, or are not postmenopausal (no menses for at least 1 year) and are of childbearing potential and not using an accepted method of birth control (surgical sterilization, intrauterine contraceptive device, oral contraceptive, diaphragm, or condom in combination with contraceptive cream, jelly, or foam or abstinence) Participated in another investigational drug/biologic or medical device study within 30 days of surgery or will be enrolled in another investigational drug or medical device study, or any study in which active subject participation is required outside routine hospital data collection during the course of the study Illicit drug use or alcohol abuse based on medical history, or currently engaged in illicit drug use or alcohol abuse Uses of supplemental ginger, ginseng, or Zanthoxylum fruit within 72 hours before randomization Has a history of allergic reactions to ginseng, ginger, Zanthoxylum fruit, or lactose Has clinical symptoms of lactose intolerance after ingesting milk or milk-containing products (abdominal pain, flatulence, diarrhea) Unwilling or unable to comply with procedures described in this protocol or is otherwise unacceptable for enrollment in the opinion of the investigator Has a history of previous surgeries, illness (interstitial pneumonia), or behavior (depression, psychosis) that, in the opinion of the investigator, might confound the study results or pose additional risk in administering the study procedures
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rebekah McLaughlin
Phone
919-341-3318
Email
rebecca.mclaughlin@syneoshealth.com
First Name & Middle Initial & Last Name or Official Title & Degree
Dana Kappel
Phone
919-745-2818
Email
dana.kappel@syneoshealth.com
Facility Information:
Facility Name
Florence Site
City
Florence
State/Province
Alabama
ZIP/Postal Code
35630
Country
United States
Individual Site Status
Recruiting
Facility Name
Gilbert Site
City
Gilbert
State/Province
Arizona
ZIP/Postal Code
85234
Country
United States
Individual Site Status
Recruiting
Facility Name
Little Rock Site
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Individual Site Status
Recruiting
Facility Name
Duarte Site
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Individual Site Status
Recruiting
Facility Name
Los Angeles Site #1
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Individual Site Status
Recruiting
Facility Name
Los Angeles Site #2
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Individual Site Status
Recruiting
Facility Name
Palo Alto Site
City
Palo Alto
State/Province
California
ZIP/Postal Code
94304
Country
United States
Individual Site Status
Recruiting
Facility Name
Sacramento Site
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Individual Site Status
Recruiting
Facility Name
Danbury Site
City
Danbury
State/Province
Connecticut
ZIP/Postal Code
06810
Country
United States
Individual Site Status
Recruiting
Facility Name
Clearwater Site
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33756
Country
United States
Individual Site Status
Recruiting
Facility Name
Miami Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33155
Country
United States
Individual Site Status
Withdrawn
Facility Name
Orlando Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
Individual Site Status
Recruiting
Facility Name
Tampa Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33606
Country
United States
Individual Site Status
Recruiting
Facility Name
Weston Site
City
Weston
State/Province
Florida
ZIP/Postal Code
33331
Country
United States
Individual Site Status
Recruiting
Facility Name
Chicago Site #2
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Name
Chicago Site #1
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Individual Site Status
Recruiting
Facility Name
Urbana Site
City
Urbana
State/Province
Illinois
ZIP/Postal Code
61801
Country
United States
Individual Site Status
Recruiting
Facility Name
Lexington Site
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536
Country
United States
Individual Site Status
Recruiting
Facility Name
Louisville Site
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Individual Site Status
Withdrawn
Facility Name
Metairie Site
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70006
Country
United States
Individual Site Status
Recruiting
Facility Name
Baltimore Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21237
Country
United States
Individual Site Status
Withdrawn
Facility Name
Boston Site #2
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Withdrawn
Facility Name
Boston Site #1
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Recruiting
Facility Name
Detroit Site
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Individual Site Status
Recruiting
Facility Name
St. Louis Site
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Name
Newark Site
City
Newark
State/Province
New Jersey
ZIP/Postal Code
07103
Country
United States
Individual Site Status
Terminated
Facility Name
Mineola Site
City
Mineola
State/Province
New York
ZIP/Postal Code
11501
Country
United States
Individual Site Status
Recruiting
Facility Name
New York Site
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Name
Stony Brook Site
City
Stony Brook
State/Province
New York
ZIP/Postal Code
11794
Country
United States
Individual Site Status
Recruiting
Facility Name
Cleveland Site #2
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44111
Country
United States
Individual Site Status
Recruiting
Facility Name
Cleveland Site #1
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Recruiting
Facility Name
Dayton Site
City
Dayton
State/Province
Ohio
ZIP/Postal Code
45409
Country
United States
Individual Site Status
Withdrawn
Facility Name
Philadelphia Site #2
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19140
Country
United States
Individual Site Status
Recruiting
Facility Name
Philadelphia Site #1
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19141
Country
United States
Individual Site Status
Withdrawn
Facility Name
Pittsburgh Site
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15212
Country
United States
Individual Site Status
Recruiting
Facility Name
Charleston Site
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Individual Site Status
Recruiting
Facility Name
Memphis Site
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38120
Country
United States
Individual Site Status
Recruiting
Facility Name
Dallas Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Individual Site Status
Terminated
Facility Name
Fort Worth Site
City
Fort Worth
State/Province
Texas
ZIP/Postal Code
76104
Country
United States
Individual Site Status
Recruiting
Facility Name
Salt Lake City Site
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84132
Country
United States
Individual Site Status
Recruiting
Facility Name
Roanoke Site
City
Roanoke
State/Province
Virginia
ZIP/Postal Code
24014
Country
United States
Individual Site Status
Recruiting
Facility Name
Milwaukee Site
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection

We'll reach out to this number within 24 hrs